Opioid Pharmacotherapy for Chronic Noncancer Pain: The American Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chronic noncancer pain is a significant and growing public health challenge in the United States. Lacking effective alternative interventions for effective chronic noncancer pain management, many physicians have turned to opioid pharmacotherapy. Increased opioid prescribing brings not only gains in therapeutic benefit but also a higher incidence of adverse drug events including increased medication misuse and opioid related mortality. Currently the United States must confront the dual problems of widespread undertreated chronic noncancer pain and a prescription opioid abuse crisis. Withholding pain relieving drugs from patients in need is unjustifiable, yet drug diversion, abuse and adverse drug events have become major social as well as medical problems. At the heart of this crisis is the lack of definitive evidence about the risk to benefit ratio of opioid pharmacotherapy for chronic noncancer pain both on an individual case and on a population basis. This article describes the extent and severity of the American chronic noncancer pain problem and the history of opioid pharmacotherapy for chronic noncancer pain in the United States. It then discusses the concept of evidence based practice and reviews current evidence supporting opioid pharmacotherapy for chronic noncancer pain as well as adverse drug events related to opioid pharmacotherapy including misuse and abuse. Finally, it considers the conflict of providing pain relief versus protecting society and reviews steps that governmental agencies, industry and others are taking to contain and ultimately resolve the problems of excessive prescribing and conflicting priorities.
Abstract
Chronic noncancer pain is a significant and growing public health challenge in the United States. Lacking effective alternative interventions for effective chronic noncancer pain management, many physicians have turned to opioid pharmacotherapy. Increased opioid prescribing brings not only gains in therapeutic benefit but also a higher incidence of adverse drug events including increased medication misuse and opioid related mortality. Currently the United States must confront the dual problems of widespread undertreated chronic noncancer pain and a prescription opioid abuse crisis. Withholding pain relieving drugs from patients in need is unjustifiable, yet drug diversion, abuse and adverse drug events have become major social as well as medical problems. At the heart of this crisis is the lack of definitive evidence about the risk to benefit ratio of opioid pharmacotherapy for chronic noncancer pain both on an individual case and on a population basis. This article describes the extent and severity of the American chronic noncancer pain problem and the history of opioid pharmacotherapy for chronic noncancer pain in the United States. It then discusses the concept of evidence based practice and reviews current evidence supporting opioid pharmacotherapy for chronic noncancer pain as well as adverse drug events related to opioid pharmacotherapy including misuse and abuse. Finally, it considers the conflict of providing pain relief versus protecting society and reviews steps that governmental agencies, industry and others are taking to contain and ultimately resolve the problems of excessive prescribing and conflicting priorities.
참고문헌 (41)
- Committee on Advancing Pain Research, Care, and Education, "Relieving pain in America: a blueprint for transforming prevention, care, education, and research" (2011), The National Academies Press
- Croft P, "Chronic pain epidemiology from aetiology to public health" (2010), Oxford University Press
- International Narcotics Control Board, "The Report of the International Narcotics Control Board for 2010" (2011), United Nations Press
- Lipton RB, "Chronic migraine, classification, differential diagnosis, and epidemiology", Headache, 51(Suppl 2), pp.77~83 (2011)
- McCarthy LH, "Chronic pain and obesity in elderly people: results from the Einstein aging study", J Am Geriatr Soc, 57, pp.115~119 (2009)
- Mathus-Vliegen EM, "Obesity and the elderly", J Clin Gastroenterol, 46, pp.533~544 (2012)
- Gaskin DJ, "The economic costs of pain in the United States", J Pain, 13, pp.715~724 (2012)
- Multidisciplinary pain programs for chronic noncancer pain, "Jeffery MM", Agency for Healthcare Research and Quality, ~, pp.Technical brief No. 8 (2011)
- Portenoy RK, "Chronic use of opioid analgesics in non-malignant pain: report of 38 cases", Pain, 25, pp.171~186 (1986)
- "The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society", Clin J Pain, 13, pp.6~8 (1997)
- The Federation of State Medical Boards of The United States, Inc., "Model guidelines for the use of controlled substances for the treatment of pain", S D J Med, 52, pp.25~27 (1999)
- Sackett DL, "Evidence based medicine: what it is and what it isn't", BMJ, 312, pp.71~72 (1996)
- Portenoy RK, "Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study", Clin J Pain, 23, pp.287~299 (2007)
- Ballantyne JC, "Opioid therapy for chronic pain", N Engl J Med, 349, pp.1943~1953 (2003)
- Papaleontiou M, "Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis", J Am Geriatr Soc, 58, pp.1353~1369 (2010)
- Carson S, "Drug class review: long-acting opioid analgesics" (2011), Oregon Evidence-based Practice Center, Oregon Health & Sciences University
- Moore RA, "Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids", Arthritis Res Ther, 7, pp.R1046~R1051 (2005)
- Elliott JA, "Non-Analgesic Effects of Opioids: Opioids and The Endocrine System", Curr Pharm Des (2012)
- Merza Z, "Chronic use of opioids and the endocrine system", Horm Metab Res, 42, pp.621~626 (2010)
- Andrews CM, "Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation", Cardiol J, 16, pp.210~217 (2009)
- Lee M, "A comprehensive review of opioid-induced hyperalgesia", Pain Physician, 14, pp.145~161 (2011)
- Brack A, "Immunosuppressive effects of opioids--clinical relevance", J Neuroimmune Pharmacol, 6, pp.490~502 (2011)
- Warner M, "Drug poisoning deaths in the United States, 1980-2008", NCHS Data Brief, pp.1~8 (2011)
- Manchikanti L, "Opioid epidemic in the United States", Pain Physician, 15, pp.ES9~ES38 (2012)
- Birnbaum HG, "Societal costs of prescription opioid abuse, dependence, and misuse in the United States", Pain Med, 12, pp.657~667 (2011)
- Colburn JL, "Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic", J Opioid Manag, 8, pp.153~160 (2012)
- Von Korff M, "Long-term opioid therapy reconsidered", Ann Intern Med, 155, pp.325~328 (2011)
- Cepeda MS, "Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US", Drug Saf, 35, pp.325~334 (2012)
- Cepeda MS, "Opioid shopping behavior: how often, how soon, which drugs, and what payment method", J Clin Pharmacol (2012)
- Fishbain DA, "What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse", addiction and, Pain Med, pp.2008, 9[DOI]
- Boscarino JA, "Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria", J Addict Dis, 30, pp.185~194 (2011)
- Rigg KK, "Patterns of prescription medication diversion among drug dealers", Drugs (Abingdon Engl), 19, pp.144~155 (2012)
- Hall AJ, "Patterns of abuse among unintentional pharmaceutical overdose fatalities", JAMA, 300, pp.2613~2620 (2008)
- Webster L, "Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain", J Opioid Manag, 7, pp.235~245 (2011)
- Webster LR, "An analysis of the root causes for opioid-related overdose deaths in the United 1. States", Pain Med, 12(Suppl 2), pp.S26~S35 (2011)
- Chapman CR, "Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base", J Pain, 11, pp.807~829 (2010)
- Fishman SM, "Responsible opioid prescribing: a clinician's guide. 2nd ed" (2012), Waterford Life Sciences
- Office of National Drug Control Policy, "Epidemic: responding to America's prescription drug abuse crisis", pp.10~ (2011), US Government
- Gudin J, "Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice", J Pain Palliat Care Pharmacother, 26, pp.136~143 (2012)
- Schneider JP, "Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?", CNS Drugs, 24, pp.805~810 (2010)
- Raffa RB, "Opioid formulations designed to resist", deter abuse, 2010, pp.70, 1657~1675